A post hoc analysis reports the oral GLP-1 medication orforglipron was associated with similar weight reductions across pre, peri, and postmenopausal women.
A post hoc analysis of the phase 3 ATTAIN-1 and ATTAIN-2 trials scheduled for presentation at the September 2026 European Association for the Study of Diabetes annual meeting reported that the oral GLP-1 medication orforglipron was associated with weight reductions across premenopausal, perimenopausal and postmenopausal subgroups.
Historically, clinicians evaluating weight management therapies for midlife women had to rely on broad trial data that did not differentiate outcomes by hormonal stage. A 2026 review published in PubMed Central noted that evidence specific to midlife and postmenopausal women remains limited across second-line therapies. Because dedicated data remained sparse, medical professionals often extrapolated general adult outcomes to women experiencing menopausal transitions. This left a notable gap in understanding whether shifting hormonal profiles alter a patient's response to modern weight medications.
Without subgroup analyses detailing responses across distinct reproductive stages, clinical guidance often treated female patients as a single broad category. The lack of specific data made it difficult to form precise expectations for women navigating hormonal changes during menopause. Practitioners had limited evidence to explain how medications might perform as a woman's body composition and metabolic baseline changed over time. Consequently, treatment plans relied on the assumption that transition status did not materially alter therapeutic efficacy.
The recent findings stem from post hoc subgroup analyses of two distinct clinical trials analyzing the non-peptide GLP-1 receptor agonist orforglipron. These analyses assessed total weight, waist circumference, waist-to-height ratio and the proportions of participants reaching specific weight loss thresholds. Researchers measured these clinical outcomes at week 72 of the trials. It is necessary to note that these were post hoc analyses rather than trials designed originally to test whether menopausal stage changes treatment response.
The two trials focused on different patient populations facing distinct metabolic conditions. ATTAIN-1 enrolled people with overweight or obesity who did not have a diabetes diagnosis. ATTAIN-2 specifically enrolled individuals managing overweight or obesity alongside type 2 diabetes. Within these structures, eligible women had obesity or overweight combined with at least one weight-related medical condition.
To understand the trial applications, one must look at the established clinical parameters for this medication. The US Food and Drug Administration lists Foundayo, the brand name for orforglipron, as approved on April 1, 2026. This approval covers adults with obesity or adults with overweight who have at least one weight-related comorbidity. The FDA explicitly indicates the medication for use strictly in combination with reduced-calorie eating and increased physical activity to maintain long-term weight reduction.
The FDA maintains strict lifestyle requirements for the use of this medication to support long-term metabolic health. The agency pairs the approval directly with a requirement for conscious nutrition and consistent movement. The menopausal subgroup analysis does not overwrite this core requirement or create a standalone indication for midlife women. Medical professionals must still evaluate the treatment as a component of a comprehensive physical health plan rather than an isolated fix.
In the ATTAIN-1 trial, women taking 36 milligrams of orforglipron reported substantial mean weight reductions at the 72-week mark. Medscape reported these mean reductions reached 12.81 percent before menopause, 14.38 percent during perimenopause and 14.07 percent after menopause. The corresponding placebo groups saw minimal changes during the same timeframe. Specifically, the reported placebo reductions were 0.25 percent, 1.02 percent and 0.62 percent across the three respective menopausal categories.
The ATTAIN-2 trial demonstrated a similar overall pattern among women managing type 2 diabetes. The reported weight reductions on 36 milligrams were 11.30 percent, 8.88 percent and 13.62 percent across the premenopausal, perimenopausal and postmenopausal groups. In comparison, the placebo groups experienced reductions of 2.88 percent, 1.57 percent and 2.00 percent. Medscape reported that the medication showed statistical significance versus placebo in all three menopausal groups across both clinical trials.
Beyond mean percentage changes, the analyses measured how many women reached specific clinical weight targets. MedicalXpress noted that the treatment-associated weight reduction reached up to 14 percent across all three menopausal groups. Reaching the initial clinical threshold was common among the treated participants. MedicalXpress reported that up to 83 percent of women receiving orforglipron lost at least 5 percent of their body weight, compared with up to 30 percent on placebo.
Medscape provided separate reporting on the proportions of women hitting these designated targets. According to Medscape, more than 80 percent of ATTAIN-1 participants on orforglipron reached the 5 percent weight loss threshold across menopausal stages. This compared with roughly 20 to 25 percent of participants who received the placebo. These figures highlight the broad contrast in group outcomes between the active medication and the placebo interventions.
The researchers also evaluated shifts in waist measurements during the trials to provide localized structural data. MedicalXpress reported waist circumference reductions of up to 12.5 centimeters, which is approximately 4.9 inches. These waist measurements offer structural context alongside total body weight changes for women undergoing metabolic shifts. However, these reports do not show that waist change alone predicts an individual's total health improvement or subsequent physical energy.
When evaluating post hoc analyses, reading the specific structural details of the data provides necessary context. MedicalXpress reported that treatment and placebo groups within the menopausal categories ranged from 142 to 225 women. Conversely, Medscape reported subgroup sizes ranging from 10 to 225 across the two trials. Because subgroup counts differ depending on the report's description, readers must treat fine-grained subgroup comparisons cautiously until the underlying conference abstract clarifies the denominators.
The available summaries do not definitively establish that clinical outcomes are statistically equivalent across all menopausal stages. Medscape noted that no limitations were explicitly mentioned in the initial conference abstract. The results were scheduled for reporting ahead of an EASD presentation, meaning the sources do not provide a full peer-reviewed paper for this specific menopausal status analysis. Medscape reported that the study was funded by Eli Lilly and that all authors disclosed being Lilly employees.
MedicalXpress identified Hunter Thomas Hoffman of Eli Lilly as one of the study authors. Medscape added that the analysis was led by Andreea Ciudin Mihai of Hospital Universitari Vall d'Hebron. The authors wrote that the findings demonstrate the medication's efficacy across menopausal stages, but the reporting lacks a separate independent clinician's commentary on these subgroup findings. Furthermore, the available event reports do not establish effects on menopause symptoms, muscle health, bone density or sexual wellbeing.
For women considering medical weight management, these reported results offer preliminary reassurance that weight reduction occurred in each menopausal stage subgroup. However, they do not prove that individual responses will be identical or that a woman's hormonal stage is entirely irrelevant to her overall care. The reported values represent study averages and group outcomes rather than promised individual forecasts. Subgroup findings should never be used to guarantee a particular percentage of weight loss for any single patient.
The subgroup analysis does not create a new menopause-specific indication for the medication. A comprehensive discussion with a qualified clinician can address whether an FDA-approved medication fits a person's health history, eligibility and long-term goals. The FDA places this treatment alongside reduced-calorie eating and increased physical activity rather than presenting the drug as a standalone intervention. Evaluating medications during this life stage requires careful attention to how treatments intersect with metabolic health and changing body composition over time.
A separate 2026 review of obesity pharmacotherapy notes that optimal maintenance dose and treatment duration for preserving response remain unresolved research priorities. This broad point is highly relevant to long-term treatment discussions for women entering their midlife years. Balancing medical therapies with practical nutritional strategies remains critical for preserving lean muscle and functional strength. Patients should prioritize consistent lifestyle habits alongside any prescribed pharmacological support to achieve balanced long-term outcomes.
Moving forward, these subgroup analyses will likely help clinicians provide midlife women with more specific data on oral GLP-1 outcomes across menopausal stages, shifting practice away from relying solely on broad adult averages.
While your endocrinologist or general practitioner handles your specific medication approvals and physical monitoring day to day, navigating the surrounding science becomes remarkably clear when Refemina analyzes the research. We address the difficulty finding practical nutrition guidance that is not based on restriction or fads, helping you align clinical treatments with sustainable daily habits. Explore Resources
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources